Pharmaceutical Technology's In the Lab eNewsletter
3M Drug Delivery Systems UK organization has revealed that it is relocating its R&D team to the Charnwood Campus, which is an officially designated Life Sciences Opportunity Zone in Loughborough, United Kingdom
In an April 1, 2019 press statement, 3M Drug Delivery Systems (DDS) UK organization has revealed that it is relocating its R&D team to the Charnwood Campus, which is an officially designated Life Sciences Opportunity Zone (LSOZ) in Loughborough, United Kingdom.
The new R&D site is located in more than 1300 m2 of laboratory space, which has been configured specifically for the development of inhalation therapies to treat respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD). The overhaul and modernization of the property took two years to complete.
“I’m delighted that 3M’s DDS Division has moved its R&D lab to Charnwood Campus. 3M’s work in the field of life sciences, producing pharmaceuticals and cutting-edge med tech, makes it one of the most innovative enterprises in Leicester and Leicestershire,” said Kevin Harris, chair, Leicester and Leicestershire Enterprise Partnership. “I’m particularly pleased that 3M is able to take advantage of Charnwood Campus’ dual designation as both an Enterprise Zone and the UK’s first Life Sciences Opportunity Zone. LSOZ status means greater collaboration between academia and industry, to drive forward the life-saving discoveries of tomorrow.”
“This move is very exciting because most of our incredible UK-based R&D team will now be working together closer than before to pursue groundbreaking innovations in the field of drug delivery technology,” added Silvia Perez, 3M DDS, president and general manager. “Improved collaboration, networking, and interaction between the business and R&D functions is beneficial to reaching our goals.”
Source: 3M
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
INTERPHEX 2025: Use of Walk-In Chambers for Bio/Pharma Development and Manufacturing
April 2nd 2025Sitting down with the PharmTech Group at INTERPHEX 2025, Christopher Murphy, director of Global Business Development and Service Customer Support at Environmental Specialties, discusses the design and critical role of walk-in chambers in the bio/pharmaceutical industry.